CAMBRIDGE, Mass.--(Business Wire)--
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced
today that David S. Barlow, Chairman and Chief Executive Officer of
Molecular Insight Pharmaceuticals, Inc., will present on two occasions
at the 10th Annual BIO CEO & Investor Conference at the
Waldorf=Astoria Hotel in New York, New York. On February 11, 2008, Mr.
Barlow will participate in an opening plenary panel called, "Check
Your Options: Raising Public and Private Financing in Today's
Marketplace", where he will offer his expert insight on the current
life sciences financing climate. On February 12, 2008, Mr. Barlow will
present an overview of Molecular Insight and its pipeline of molecular
radiotherapeutic and molecular imaging pharmaceutical candidates.
Opening Plenary Panel
"Check Your Options: Raising Public and Private Financing in
Today's Marketplace, Part II"
Monday, February 11, 2008
4:15 pm - 5:30 pm Eastern Time
Jade Room
Molecular Insight Pharmaceuticals, Inc. Company Presentation
Tuesday, February 12, 2008
9:30 am - 10:10 am Eastern Time
Louis XVI Center
The Molecular Insight company presentation will be webcast live at
www.corporate-ir.net/ireye/conflobby.zhtml?ticker=MIPI&item_id=1752407
and will be archived for one year. It will also be available in the
Investor Relations section of the Molecular Insight Pharmaceuticals
website at www.molecularinsight.com.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a
biopharmaceutical company specializing in the emerging field of
molecular medicine, applying innovations in the identification and
targeting of disease at the molecular level to improve healthcare for
patients with life-threatening diseases. The company is focused on
discovering, developing and commercializing innovative, molecular
radiotherapeutics and molecular imaging pharmaceuticals with initial
applications in the areas of oncology and cardiology. Its lead
molecular radiotherapeutic product candidates, Azedra and Onalta, are
being developed for detection and treatment of cancer. The company's
lead molecular imaging pharmaceutical product candidate, Zemiva, is
being developed for the diagnosis of cardiac ischemia, or insufficient
blood flow to the heart. In addition, the company has a growing
pipeline of product candidates resulting from application of its
proprietary platform technologies to new and existing compounds.
Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts
and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in
nature constitute "forward-looking statements." Such statements
include, but are not limited to, statements about the development of
Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates.
Such forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause the actual results of
Molecular Insight to be materially different from historical results
or from any results expressed or implied by such forward-looking
statements. These factors include, but are not limited to, risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval for product candidates;
competition from other pharmaceutical or biotechnology companies; and
the additional risks discussed in filings with the Securities and
Exchange Commission. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Molecular Insight
undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof.
Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications & Investor
Relations
Copyright Business Wire 2008
